Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...
Recursion is using AI and machine learning to accelerate drug research and development. The stock has been under pressure amid an uncertain near-term financial outlook. Several clinical updates from ...
Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results